WO2001032128A3 - Human chemokine beta-13 - Google Patents

Human chemokine beta-13 Download PDF

Info

Publication number
WO2001032128A3
WO2001032128A3 PCT/US2000/030237 US0030237W WO0132128A3 WO 2001032128 A3 WO2001032128 A3 WO 2001032128A3 US 0030237 W US0030237 W US 0030237W WO 0132128 A3 WO0132128 A3 WO 0132128A3
Authority
WO
WIPO (PCT)
Prior art keywords
ckβ
methods
protein
immune system
related disorders
Prior art date
Application number
PCT/US2000/030237
Other languages
French (fr)
Other versions
WO2001032128A9 (en
WO2001032128A2 (en
Inventor
Stephen Ullrich
George Seibel
Haodong Li
Francis W Luscinskas
Original Assignee
Human Genome Sciences Inc
Brigham & Womens Hospital
Smithkline Beecham Corp
Stephen Ullrich
George Seibel
Haodong Li
Francis W Luscinskas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Human Genome Sciences Inc, Brigham & Womens Hospital, Smithkline Beecham Corp, Stephen Ullrich, George Seibel, Haodong Li, Francis W Luscinskas filed Critical Human Genome Sciences Inc
Priority to AU15813/01A priority Critical patent/AU1581301A/en
Priority to EP00978340A priority patent/EP1229795A4/en
Priority to JP2001534336A priority patent/JP2003514517A/en
Priority to CA002387808A priority patent/CA2387808A1/en
Publication of WO2001032128A2 publication Critical patent/WO2001032128A2/en
Publication of WO2001032128A3 publication Critical patent/WO2001032128A3/en
Publication of WO2001032128A9 publication Critical patent/WO2001032128A9/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/521—Chemokines
    • C07K14/523—Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The present invention relates to a novel CKβ-13 protein which is a member of the chemokine family. In particular, isolated nucleic acid molecules are provided encoding the human CKβ-13 protein. CKβ-13 polypeptides are also provided as are vectors, host cells and recombinant methods for producing the same. The invention further relates to screening methods for identifying agonists and antagonists of CKβ-13 activity. Also provided are diagnostic methods for detecting immune system-related disorders and therapeutic methods for treating immune system-related disorders.
PCT/US2000/030237 1999-11-03 2000-11-02 Human chemokine beta-13 WO2001032128A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
AU15813/01A AU1581301A (en) 1999-11-03 2000-11-02 Human chemokine beta-13
EP00978340A EP1229795A4 (en) 1999-11-03 2000-11-02 Human chemokine beta-13
JP2001534336A JP2003514517A (en) 1999-11-03 2000-11-02 Human chemokine β-13
CA002387808A CA2387808A1 (en) 1999-11-03 2000-11-02 Human chemokine beta-13

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43276899A 1999-11-03 1999-11-03
US09/432,768 1999-11-03

Publications (3)

Publication Number Publication Date
WO2001032128A2 WO2001032128A2 (en) 2001-05-10
WO2001032128A3 true WO2001032128A3 (en) 2001-11-08
WO2001032128A9 WO2001032128A9 (en) 2002-05-16

Family

ID=23717510

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/030237 WO2001032128A2 (en) 1999-11-03 2000-11-02 Human chemokine beta-13

Country Status (5)

Country Link
EP (1) EP1229795A4 (en)
JP (1) JP2003514517A (en)
AU (1) AU1581301A (en)
CA (1) CA2387808A1 (en)
WO (1) WO2001032128A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7018627B1 (en) 1995-06-07 2006-03-28 Icos Corporation Macrophage derived chemokine (MDC), MDC analogs, MDC inhibitor substances, and uses thereof
US20060228331A1 (en) 2003-10-10 2006-10-12 Novo Nordisk A/S IL-21 Derivatives and variants
CA2542662A1 (en) * 2003-10-17 2005-04-28 Novo Nordisk A/S Pharmaceutical combinations comprising il-21

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039521A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-13

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69631971D1 (en) * 1995-11-30 2004-04-29 Us Government C-C CHEMOKINES THAT PREVENT RETOVIRUS INFECTION
CA2277580A1 (en) * 1996-12-05 1998-06-11 Human Genome Sciences, Inc. Human chemokine beta-13

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996039521A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human chemokine beta-13

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP1229795A4 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6737513B1 (en) 1996-06-07 2004-05-18 Icos Corporation Macrophage derived chemokine (MDC) and chemokine analogs and assay to identify modulators of MDC activity, and therapeutic uses for same

Also Published As

Publication number Publication date
EP1229795A2 (en) 2002-08-14
JP2003514517A (en) 2003-04-22
WO2001032128A9 (en) 2002-05-16
AU1581301A (en) 2001-05-14
CA2387808A1 (en) 2001-05-10
WO2001032128A2 (en) 2001-05-10
EP1229795A4 (en) 2004-07-28

Similar Documents

Publication Publication Date Title
CA2266439A1 (en) Neutrokine .alpha.
AU9482498A (en) Interleukin-17 receptor-like protein
WO1998031818A3 (en) Tace-like and matrilysin-like polypeptides
WO1998031806A3 (en) Fc receptors and polypeptides
WO1998030694A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
WO1998033920A3 (en) Tissue factor pathway inhibitor-3
EP1015468A4 (en) Follistatin-3
NZ510367A (en) Interleukin 17-like receptor protein nucleic acid sequence encoding the interleukin receptor protein and method of expressing protein in recombinant vector
WO2001055310A8 (en) Nucleic acids, proteins, and antibodies
EP0837131A3 (en) Staphylococcus fibronectin binding protein compounds
WO2000043493A8 (en) Metalloproteinase adam 22
WO2000052136A3 (en) Human glycosylation enzymes
WO1998011234A3 (en) Human protein kinases
WO2000067793A8 (en) Death domain containing receptor 4
DE69841751D1 (en) Chemokin alpha-5
WO2001032128A3 (en) Human chemokine beta-13
WO2003083078A3 (en) Novel human cell surface protein with immunoglobulin folds, bgs-19
WO2003027231A3 (en) Polynucleotide encoding adapter protein, pmn29
EP0990000A4 (en) Connective tissue growth factor-3
WO2003031566A3 (en) Keratinocyte derived interferon
WO2000039136A3 (en) Human brainiac-5
WO1998025957A3 (en) Human prt1-like subunit protein (hprt1) and human eif4g-like protein (p97) genes
WO2002018622A3 (en) TUMOR NECROSIS FACTOR RECEPTORS 6α AND 6$g(b)
AU5166200A (en) Human tumor necrosis factor receptor tr10
EP1712631A3 (en) Fc receptors and polypeptides

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 2387808

Country of ref document: CA

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2001 534336

Kind code of ref document: A

Format of ref document f/p: F

AK Designated states

Kind code of ref document: C2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: C2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

COP Corrected version of pamphlet

Free format text: PAGES 1/9-9/9, DRAWINGS, REPLACED BY NEW PAGES 1/9-9/9; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE

WWE Wipo information: entry into national phase

Ref document number: 2000978340

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000978340

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000978340

Country of ref document: EP